ArticleCureus2025
Severe Aortic Stenosis and Regurgitation in a Young Athletic Doctor With Bicuspid Aortic Valve Managed With On-X® Mechanical Valve Replacement.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present the case of a 28-year-old athletic male physician with asymptomatic bicuspid aortic valve (BAV), diagnosed with severe aortic stenosis (AS) and moderate aortic regurgitation (AR) following self-auscultation prompted by nocturnal palpitations and chest vibrations. Echocardiography and computed tomography (CT) confirmed severe AS (peak gradient 79 mmHg, aortic valve area 0.6 cm²), moderate AR, and left ventricular hypertrophy. Due to an aortic annulus size mismatch, the Ross procedure was deemed unsuitable, and an On-X® (Artivion, Inc., Kennesaw, Georgia, United States) mechanical aortic valve was implanted. Postoperative echocardiography demonstrated a peak gradient of 11 mmHg and an ejection fraction of 55%. The patient was discharged on warfarin, aspirin, statins, beta-blockers, and calcium channel blockers with counseling on anticoagulation management. This case highlights the challenges of managing BAV in young, active patients and the role of mechanical valve replacement when anatomical constraints preclude other options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.